Mostrar el registro sencillo del ítem

dc.contributor.authorBarreiro-Alonso, Aida
dc.contributor.authorCamara-Quilez, Maria
dc.contributor.authorSalamini-Montemurri, Martin
dc.contributor.authorLamas-Maceiras, Monica
dc.contributor.authorVizoso-Vazquez, Angel
dc.contributor.authorRodriguez-Belmonte, Esther
dc.contributor.authorQuindós Varela, María 
dc.contributor.authorMartínez Iglesias, Olaia Antía
dc.contributor.authorFigueroa Conde-Valvís, Angélica
dc.contributor.authorCerdan, Maria-Esperanza
dc.date.accessioned2022-01-25T12:15:32Z
dc.date.available2022-01-25T12:15:32Z
dc.date.issued2019
dc.identifier.issn2072-6694
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/31694235es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15897
dc.description.abstractHigh mobility group box B (HMGB) proteins are pivotal in the development of cancer. Although the proteomics of prostate cancer (PCa) cells has been reported, the involvement of HMGB proteins and their interactome in PCa is an unexplored field of considerable interest. We describe herein the results of the first HMGB1/HMGB2 interactome approach to PCa. Libraries constructed from the PCa cell line, PC-3, and from patients' PCa primary tumor have been screened by the yeast 2-hybrid approach (Y2H) using HMGB1 and HMGB2 baits. Functional significance of this PCa HMGB interactome has been validated through expression and prognosis data available on public databases. Copy number alterations (CNA) affecting these newly described HMGB interactome components are more frequent in the most aggressive forms of PCa: those of neuroendocrine origin or castration-resistant PCa. Concordantly, adenocarcinoma PCa samples showing CNA in these genes are also associated with the worse prognosis. These findings open the way to their potential use as discriminatory biomarkers between high and low risk patients. Gene expression of a selected set of these interactome components has been analyzed by qPCR after HMGB1 and HMGB2 silencing. The data show that HMGB1 and HMGB2 control the expression of several of their interactome partners, which might contribute to the orchestrated action of these proteins in PCa.en
dc.language.isoenges
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleCharacterization of HMGB1/2 Interactome in Prostate Cancer by Yeast Two Hybrid Approach: Potential Pathobiological Implicationsen
dc.typeArtigoes
dc.identifier.doi10.3390/cancers11111729
dc.identifier.pmid31694235
dc.identifier.sophos32265
dc.issue.number11es
dc.journal.titleCancers (Basel)es
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Biomédica da Coruña (INIBIC)es
dc.relation.publisherversionhttps://res.mdpi.com/d_attachment/cancers/cancers-11-01729/article_deploy/cancers-11-01729.pdfes
dc.rights.accessRightsopenAccesses
dc.subject.keywordINIBICes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number11es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional